查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2020076

肺癌筛检市场规模、份额、成长及全球产业分析：按类型、应用和地区分類的洞察，2026-2034 年预测

Lung Cancer Screening Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 139 Pages | 商品交期: 请询问到货日

价格

肺癌筛检市场的成长要素

全球肺癌筛检市场预计在2025年达到38.4亿美元，2026年成长至41.6亿美元，到2034年达到86.7亿美元，2026年至2034年的复合年增长率为9.61%。北美市场领先，在2025年占据55.13%的市场份额，这得益于其强大的筛检项目和先进的医疗基础设施。

肺癌主要与吸烟有关，仍然是全球最常见、最致命的癌症之一。早期筛检在降低死亡率方面起着至关重要的作用，这极大地促进了全球先进诊断技术的应用。

市场趋势

筛检技术的进步

市场正经历快速的技术进步，尤其是在低剂量CT（LDCT）、液态生物检体和人工智慧诊断工具等筛检方法方面。这些创新在提高早期检出率的同时，也减少了侵入性手术的需求。

奈米颗粒感测器和人工智慧辅助成像等新型技术正在显着提高筛检的准确性和效率。此外，液态生物检体的发展使得非侵入性癌症检测成为可能，让筛检更加便捷，减轻了患者的负担。

市场成长要素

肺癌发生率上升

全球肺癌发生率的上升（主要归因于吸烟和生活方式的改变）是推动市场成长的主要因素。人们对早期诊断意识的提高以及医疗机构筛检力度的加大，进一步促进了市场扩张。

政府计画和宣传宣传活动鼓励高风险族群定期接受筛检，导致每年进行的诊断测试数量增加。

先进诊断工具的广泛应用

除了先进的成像技术日益普及，已开发国家优惠的保险报销政策也推动了筛检方案的采用。此外，生物技术公司与医疗保健公司之间的合作正在加速诊断技术的创新。

抑制因子

筛检测试高成本

儘管技术不断进步，但筛检测试（尤其是电脑断层扫描）的高成本仍然是中低收入国家推广应用的一大障碍。有限的保险覆盖范围和不足的医疗基础设施进一步限制了这些测试的普及。

此外，发展中地区熟练的放射科医生和诊断专家的短缺也对市场成长构成挑战。

市场区隔分析

按类型分類的癌症

从市场区隔来看，肺癌分为非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）。

  • 非小细胞肺癌 (NSCLC) 细分市场占据主导地位，由于其在全球范围内的高发病率，预计到 2026 年将占市场份额的 87.8%。
  • 此外，由于人们对小细胞肺癌（SCLC）的认识提高和筛检力度加大，SCLC 市场也为市场做出了重大贡献。

透过诊断方法

市场分为低剂量螺旋电脑断层扫描和胸部X光检查。

  • 由于低剂量电脑断层扫描将占据市场主导地位，市场份额将达到 93.94%。
  • 由于胸部X光检查的有效性较低，因此其使用频率正在降低。

最终用户

市场涵盖医院、诊所和诊断中心。

  • 医院和诊所凭藉其完善的基础设施和强大的患者支持，预计到 2026 年将占据 70.79% 的市场份额，引领市场。
  • 由于合作伙伴关係的增加和服务范围的扩大，预计该诊断中心将稳步发展。

区域趋势

北美洲

预计北美地区到 2025 年将达到 21.1 亿美元，到 2026 年将达到 23.1 亿美元。全面的筛检计划和较高的疾病盛行率支撑了该地区的领先地位。

欧洲

预计到2025年，欧洲的烟草市场规模将达到11.5亿美元，到2026年将成长至12.4亿美元。这一增长是由吸烟率上升和完善的医疗保健体系所推动的。

亚太地区

预计亚太地区烟草市场规模在2025年将达3.8亿美元，在2026年将达4.1亿美元。烟草消费量的成长和政府的各项措施正在推动这项成长。

其他的

  • 拉丁美洲：1.6亿美元（2025年）→ 1.7亿美元（2026年）
  • 中东和非洲：3000万美元（2025年）→ 3000万美元（2026年）

由于医疗基础设施的改善，预计这些地区将经历适度增长。

主要企业

市场上的主要企业包括皇家飞利浦公司、西门子医疗公司、佳能医疗系统株式会社、通用电气医疗集团和富士胶片控股株式会社。这些公司正致力于创新、推出新产品和建立策略联盟，以巩固其市场地位。

主要行业趋势

  • 2024年，将推出新的筛检项目和临床测试，以提高早期检测率。
  • 人工智慧辅助诊断工具和成像技术已获得监管部门核准。
  • 各公司越来越关注非侵入性筛检解决方案，例如液态生物检体。

2026-2034 年的复合年增长率为 9.61%。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 2025年主要地区肺癌发生率
  • 重大工业发展、併购和新产品发布。
  • 美国、欧洲和亚洲肺癌筛检发展的法规环境
  • 肺癌筛检的技术进步
  • 新冠疫情对肺癌筛检的影响

第五章：2021-2034年全球肺癌筛检市场分析、洞察与预测

  • 市场分析、洞察与预测：按癌症类型划分
    • 非小细胞肺癌（NSCLC）
    • 小细胞肺癌
  • 市场分析、洞察与预测：按诊断类型划分
    • 低剂量螺旋电脑断层扫描
    • 胸部X光片
  • 市场分析、洞察与预测：按最终用户划分
    • 医院和诊所
    • 诊断中心
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美肺癌筛检市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲肺癌筛检市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区肺癌筛检市场分析、洞察与预测（2021-2034年）

  • 国家
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他亚太地区

第九章：拉丁美洲肺癌筛检市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲

第十章：中东和非洲肺癌筛检市场分析、洞察和预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • Koninklijke Philips NV
    • Siemens Healthineers AG
    • GE Healthcare（General Electric Company）
    • Nuance Communications, Inc.
    • Eon
    • PenRad Technologies, Inc.
    • Volpara Solutions Limited.
    • Canon Medical Systems Corporation
    • FUJIFILM Holdings Corporation
    • Medtronic
Product Code: FBI101174

Growth Factors of lung cancer screening Market

The global lung cancer screening market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.16 billion in 2026, reaching USD 8.67 billion by 2034, registering a CAGR of 9.61% during 2026-2034. North America dominated the market with a 55.13% share in 2025, driven by strong screening programs and advanced healthcare infrastructure.

Lung cancer remains one of the most prevalent and fatal cancers worldwide, primarily linked to tobacco consumption. Early detection through screening plays a critical role in reducing mortality, which is significantly boosting the adoption of advanced diagnostic technologies globally.

Market Trends

Technological Advancements in Screening

The market is witnessing rapid technological progress, particularly in screening methods such as low-dose computed tomography (LDCT), liquid biopsy, and AI-based diagnostic tools. These innovations are improving early detection rates while reducing the need for invasive procedures.

Emerging technologies such as nanoparticle-based sensors and AI-assisted imaging are transforming screening accuracy and efficiency. Additionally, the development of liquid biopsy tests is enabling non-invasive cancer detection, making screening more accessible and patient-friendly.

Market Growth Factors

Rising Prevalence of Lung Cancer

The increasing global incidence of lung cancer, largely due to smoking and lifestyle changes, is a major driver of market growth. Growing awareness regarding early diagnosis and the rising number of screening initiatives by healthcare organizations are further supporting market expansion.

Government programs and awareness campaigns are encouraging high-risk populations to undergo regular screening, thereby increasing the number of diagnostic procedures conducted annually.

Growing Adoption of Advanced Diagnostic Tools

The increasing use of advanced imaging technologies, coupled with favorable reimbursement policies in developed countries, is driving the adoption of screening solutions. Collaborations between biotechnology and healthcare companies are also fostering innovation in diagnostic techniques.

Restraining Factors

High Cost of Screening Tests

Despite technological advancements, the high cost associated with screening procedures, especially CT scans, limits their accessibility in low- and middle-income countries. Limited insurance coverage and inadequate healthcare infrastructure further restrict widespread adoption.

Additionally, the shortage of skilled radiologists and diagnostic professionals in developing regions poses a challenge to market growth.

Market Segmentation Analysis

By Cancer Type

The market is segmented into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

  • The NSCLC segment dominates and is projected to hold 87.8% market share in 2026, owing to its higher prevalence globally.
  • The SCLC segment also contributes significantly due to rising awareness and screening initiatives.

By Diagnosis Type

The market is divided into low-dose spiral CT scans and chest X-rays.

  • The low-dose CT scan segment dominates with 93.94% share in 2026, driven by higher accuracy and proven mortality reduction benefits.
  • Chest X-rays are witnessing declining adoption due to lower effectiveness.

By End-user

The market includes hospitals & clinics and diagnostic centers.

  • Hospitals & clinics lead the market, accounting for 70.79% share in 2026, due to better infrastructure and higher patient preference.
  • Diagnostic centers are expected to grow steadily with increasing collaborations and service expansion.

Regional Insights

North America

North America accounted for USD 2.11 billion in 2025 and is projected to reach USD 2.31 billion in 2026. Strong screening programs and high disease prevalence support regional dominance.

Europe

Europe held USD 1.15 billion in 2025 and is expected to grow to USD 1.24 billion in 2026. Growth is driven by rising smoking rates and well-established healthcare systems.

Asia Pacific

Asia Pacific generated USD 0.38 billion in 2025 and is projected to reach USD 0.41 billion in 2026. Increasing tobacco consumption and government initiatives are fueling growth.

Rest of the World

  • Latin America: USD 0.16 billion (2025) -> USD 0.17 billion (2026)
  • Middle East & Africa: USD 0.03 billion (2025) -> USD 0.03 billion (2026)

These regions show gradual growth due to improving healthcare infrastructure.

Key Companies

Leading players in the market include Koninklijke Philips N.V., Siemens Healthineers AG, Canon Medical Systems Corporation, GE Healthcare, and FUJIFILM Holdings Corporation. These companies focus on innovation, product launches, and strategic partnerships to strengthen their market position.

Key Industry Developments

  • In 2024, new screening programs and clinical trials were launched to improve early detection.
  • AI-based diagnostic tools and imaging technologies received regulatory approvals.
  • Companies are increasingly focusing on non-invasive screening solutions such as liquid biopsies.

Conclusion

The lung cancer screening market is poised for strong growth, increasing from USD 3.84 billion in 2025 to USD 8.67 billion by 2034. Rising cancer prevalence, technological advancements, and government support for early diagnosis are key growth drivers. Although high costs and limited accessibility may hinder adoption in some regions, ongoing innovations and expanding screening programs will significantly enhance early detection and improve patient outcomes globally.

Growth Rate CAGR of 9.61% from 2026-2034

Segmentation By Cancer Type

  • Non-small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer

By Diagnosis Type

  • Low Dose Spiral CT Scan
  • Chest X-ray

By End User

  • Hospitals & Clinics
  • Diagnostic Centers

By Geography

  • North America (By Cancer Type, By Diagnosis Type, By End User, and By Country)
    • U.S.
    • Canada
  • Europe (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Cancer Type, By Diagnosis Type, By End User, and By Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence of Lung Cancer, By Key Region, 2025
  • 4.2. Key Industry Developments, Merger, Acquisitions, and Product Launches
  • 4.3. Regulatory Scenario Imposed on the Development of Lung Cancer Screening in U.S., Europe, and Asia
  • 4.4. Technological Advancements in Lung Cancer Screening
  • 4.5. Impact of COVID-19 on Lung Cancer Screening

5. Global Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 5.1.2. Small Cell Lung Cancer
  • 5.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 5.2.1. Low Dose Spiral CT scan
    • 5.2.2. Chest X-ray
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Diagnostic Centers
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 6.1.2. Small Cell Lung Cancer
  • 6.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 6.2.1. Low Dose Spiral CT scan
    • 6.2.2. Chest X-ray
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Diagnostic Centers
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 7.1.2. Small Cell Lung Cancer
  • 7.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 7.2.1. Low Dose Spiral CT scan
    • 7.2.2. Chest X-ray
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Diagnostic Centers
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 8.1.2. Small Cell Lung Cancer
  • 8.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 8.2.1. Low Dose Spiral CT scan
    • 8.2.2. Chest X-ray
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Diagnostic Centers
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 9.1.2. Small Cell Lung Cancer
  • 9.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 9.2.1. Low Dose Spiral CT scan
    • 9.2.2. Chest X-ray
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Diagnostic Centers
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Lung Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.1.1. Non-small Cell Lung Cancer (NSCLC)
    • 10.1.2. Small Cell Lung Cancer
  • 10.2. Market Analysis, Insights and Forecast - By Diagnosis Type
    • 10.2.1. Low Dose Spiral CT scan
    • 10.2.2. Chest X-ray
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Diagnostic Centers
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC Countries
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Koninklijke Philips N.V.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Siemens Healthineers AG
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. GE Healthcare (General Electric Company)
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Nuance Communications, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Eon
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. PenRad Technologies, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Volpara Solutions Limited.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Canon Medical Systems Corporation
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. FUJIFILM Holdings Corporation
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Medtronic
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 02: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 03: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 04: Global Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 05: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 06: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 07: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 08: North America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 09: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 10: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 11: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 12: Europe Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 14: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 15: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 18: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 19: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 20: Latin America Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Cancer Type, 2021-2034
  • Table 22: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by Diagnosis Type, 2021-2034
  • Table 23: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Lung Cancer Screening Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 01: Global Lung Cancer Screening Market Revenue Breakdown (USD Billion, %) by Region, 2025 & 2034
  • Figure 02: Global Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 03: Global Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025 & 2034
  • Figure 04: Global Lung Cancer Screening Market Value Share (%), by End User, 2025 & 2034
  • Figure 05: Global Lung Cancer Screening Market Value (USD Billion), by Region, 2025 & 2034
  • Figure 06: North America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 07: North America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 08: North America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 09: North America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 10: North America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 11: North America Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 12: North America Lung Cancer Screening Market Value (USD Billion), By Country, 2025 & 2034
  • Figure 13: North America Lung Cancer Screening Market Value Share (%), By Country, 2025
  • Figure 14: Europe Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 15: Europe Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 16: Europe Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 17: Europe Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 18: Europe Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 19: Europe Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 20: Europe Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 23: Asia Pacific Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 24: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 25: Asia Pacific Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 26: Asia Pacific Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 31: Latin America Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 32: Latin America Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 33: Latin America Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 34: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 35: Latin America Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 36: Latin America Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 37: Latin America Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Latin America Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Cancer Type, 2025 & 2034
  • Figure 40: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Cancer Type, 2025
  • Figure 41: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by Diagnosis Type, 2025 & 2034
  • Figure 42: Middle East & Africa Lung Cancer Screening Market Value Share (%), by Diagnosis Type, 2025
  • Figure 43: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), by End User, 2025 & 2034
  • Figure 44: Middle East & Africa Lung Cancer Screening Market Value Share (%), by End User, 2025
  • Figure 45: Middle East & Africa Lung Cancer Screening Market Value (USD Billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Middle East & Africa Lung Cancer Screening Market Value Share (%), By Country/ Sub-region, 2025